Skip to content
Markets News
Global1 min read

FDA Warns of Rare Vision Risk Linked to GLP-1 Drugs

Makkler Newsroom
November 13, 2026 · Based on reporting by Fortune
Photo: Pöllö / Wikimedia Commons · CC BY 3.0

FDA analyses found a small increase in NAION cases among people taking GLP-1 drugs, which are used by 30 million Americans.

Key takeaways

  • FDA analyses found a small increase in NAION cases among GLP-1 drug users.
  • One analysis found 2.6 additional cases per 100,000 people each year.
  • NAION can cause sudden vision loss and may lead to permanent impairment.

The FDA has warned of a rare eye condition linked to GLP-1 drugs, which are used by 30 million people in the U.S. The condition, NAION, can cause sudden vision loss.

An analysis of 126 clinical trials found an average of 6.4 NAION cases per 100,000 people each year among those taking GLP-1 drugs, compared with 3.8 among people given a placebo or another drug. The FDA calculated this as 2.6 extra cases per 100,000 patients annually.

A separate FDA review of real-world data on people with type 2 diabetes found 32 cases per 100,000 GLP-1 drug users over a year, versus 26 among people taking DPP-4 inhibitors. That amounted to six additional cases per 100,000 patients.

NAION is an injury to the optic nerve caused by reduced blood flow. Symptoms can include sudden, painless blurry vision, dark patches or partial vision loss, and the impairment often persists.

Ziyad Al-Aly, a clinical epidemiologist who co-authored research on the risk, described it as small but real. He said clinicians should discuss the risk with patients, who should seek immediate care at the first signs of vision problems.

Topics
LLYNVOFDAGLP-1 drugsNAION
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.